Senti Biosciences, Inc.
SNTI
Rank in Stocks
#30509
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit... Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Share Price
$0.1588
Last synced: 2026-11-09
Market Cap
$4.95M
Change (1 day)
-0.75%
Change (1 year)
-91.60%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Senti Biosciences, Inc. (SNTI)
Category
Healthcare
EPS for Senti Biosciences, Inc. (SNTI)
EPS as of June 2026 TTM: $-1.77
According to Senti Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-1.77. At the end of 2025 the company had an EPS of $-2.73, an increase over its 2024 EPS of $-11.49.
EPS history for Senti Biosciences, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.77 | -35.16% |
| 2025 | $-2.73 | -76.24% |
| 2024 | $-11.49 | -45.13% |
| 2023 | $-20.94 | 58.04% |
| 2022 | $-13.25 | 4.58% |
| 2021 | $-12.67 | 178.46% |
| 2020 | $-4.55 | -70.78% |
| 2019 | $-15.57 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -984.75% |
US
|
|
| $-7.07 | 299.44% |
US
|
|
| $-5.29 | 198.87% |
AU
|
|
| $12.88 | -827.69% |
BE
|
|
| $21.56 | -1,318.08% |
NL
|
Questions about Senti Biosciences, Inc.'s earnings per share (EPS)
What is Senti Biosciences, Inc.'s earnings per share (EPS)?
Senti Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-1.77, as of Jun 2026.
What was Senti Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Senti Biosciences, Inc.'s earnings per share (EPS) was $-2.73, compared with $-11.49 in 2024.
How has Senti Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Senti Biosciences, Inc.'s earnings per share (EPS) was highest in 2025 ($-2.73) and lowest in 2023 ($-20.94).
How does Senti Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Senti Biosciences, Inc.'s earnings per share (EPS) ($-1.77) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.